The relationship between Eastern Cooperative Oncology Group performance status and healthcare resource utilization among patients with advanced or metastatic colorectal, lung or gastric cancer

Hess, Lisa M.; Smith, David M.; Cui, Zhanglin Lin; Montejano, Leslie; Liepa, Astra M.; Schelman, William R.; Bowman, Lee

doi:10.1080/21556660.2020.1851504

Cited by 7 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We only included patients with a clinically positive regional nodal metastatic disease (patients with an N1 to N3 classification were included) and without evidence of distant metastasis at the time of the initial diagnosis. Patients' daily living performance at the initial diagnosis was assessed using the Eastern Cooperative Oncology Group scale (ECOG) [24]. Patients included in this study received curative surgery (resection of the primary tumor and mediastinal lymph node dissection) with or without neoadjuvant CCRT, definitive CCRT, or definitive radiotherapy as the initial treatment.…”

Section: Patient Populationmentioning

confidence: 99%

Prognostic Value of Combing Primary Tumor and Nodal Glycolytic–Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis

et al. 2021

View full text Add to dashboard Cite

We investigated whether the combination of primary tumor and nodal 18F-FDG PET parameters predict survival outcomes in patients with nodal metastatic non-small cell lung cancer (NSCLC) without distant metastasis. We retrospectively extracted pre-treatment 18F-FDG PET parameters from 89 nodal-positive NSCLC patients (stage IIB–IIIC). The Cox proportional hazard model was used to identify independent prognosticators of overall survival (OS) and progression-free survival (PFS). We devised survival stratification models based on the independent prognosticators and compared the model to the American Joint Committee on Cancer (AJCC) staging system using Harrell’s concordance index (c-index). Our results demonstrated that total TLG (the combination of primary tumor and nodal total lesion glycolysis) and age were independent risk factors for unfavorable OS (p < 0.001 and p = 0.001) and PFS (both p < 0.001), while the Eastern Cooperative Oncology Group scale independently predicted poor OS (p = 0.022). Our models based on the independent prognosticators outperformed the AJCC staging system (c-index = 0.732 versus 0.544 for OS and c-index = 0.672 versus 0.521 for PFS, both p < 0.001). Our results indicate that incorporating total TLG with clinical factors may refine risk stratification in nodal metastatic NSCLC patients and may facilitate tailored therapeutic strategies in this patient group.

show abstract

Section: Patient Populationmentioning

confidence: 99%

Prognostic Value of Combing Primary Tumor and Nodal Glycolytic–Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In a study, 25-30% of the patients with NSCLC were reported to be diagnosed at locally advanced stages (IIIA or IIIB). Postoperative 5-year survival rates were stated to range between 13 and 42.8% (7).…”

Section: Discussionmentioning

confidence: 99%

The Survival Efficiency of Initial Surgical Treatment in Stage IIIa-N2 Positive Non-Small Cell Lung Cancer

Beyoğlu

Gülhan²,

Öztürk³

et al. 2021

Middle Black Sea Journal of Health Science

View full text Add to dashboard Cite

Objective: The role of surgical treatment in the multimodal treatment of stage IIIA-N2 positive non-small cell lung cancer (NSCLC) patients is a matter of debate. We aim to investigate initial surgical treatment's survival efficiency in patients with IIIA N2 positive NSCLC.Methods: The patients treated for stage IIIA N2 positive NSCLC in a single center between January 2009 and December 2014 were retrospectively analyzed. A total of 134 patients with 5 cm tumors in diameter or less and without involvements of the chest wall, mediastinal pleura, phrenic nerve, recurrent laryngeal nerve, pericardium, heart, diaphragm, vertebra, esophagus, large vessel invasion, and satellite nodule were detected. Of these patients, initial surgical treatment before chemoradiotherapy was performed in 72 (Group 1), while definitive concurrent chemoradiotherapy was performed in 62 patients (Group 2). Each patient's gender, age, physical performance status, tumors size, pathological diagnosis, lung resection types, and long-term survival data were evaluated.Results: No statistically significant difference was found in patients' gender, physical performance, tumor size, and tumor histology. Survival rates were higher among patients aged ≤65 years and higher in Group 1 than Group 2. While one-, three, five-, and seven-year survival rates were detected as 86.1%, 62.5%, 41.6%, and 31% in Group 1, respectively, the rates were observed to be as 77.4%, 30.6%, 10.8%, and 6.7% in Group 2, respectively. However, no difference was seen between patients' survival rates with single and multiple ipsilateral mediastinal lymph node metastases.Conclusion: Despite those advocating surgical treatment after neoadjuvant chemotherapy in treating stage IIIA N2 positive patients, others supporting surgical treatment should initially be performed. When conducted as the first step, surgical treatment achieves significant increases in survival.

show abstract

“…This cautionary approach advises against the inclusion of patients with higher ECOG grades, which, in turn, results in an absence of evidence for this population, which it is expected to be the most predominant among advanced CG patients. The lack of data for patients with higher ECOG grades highlights a critical gap in understanding and addressing the needs of these individuals [44,45]. This emphasizes the necessity for careful consideration of these therapies when offered in clinical practice to patients with a poor PS due to the associated probable risks.…”

Section: Main Ndingsmentioning

confidence: 99%

Immunotherapy or targeted therapy versus best supportive care for advanced gastric cancer: a systematic review and meta-analysis of randomized trials

Meade,

Santero,

Savall-Esteve

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose To assess the efficacy and safety of non-chemotherapy anticancer drugs (ACDs) compared to best supportive care (BSC) or placebo for the treatment of advanced gastric cancer (GC). Methods Systematic review of randomized controlled trials (RCTs) searching (May 2022) MEDLINE, EMBASE, CENTRAL, Epistemonikos, ClinicalTrials.gov and PROSPERO. Certainty of evidence was evaluated following GRADE. Results Six RCTs included. Targeted therapies likely result in a slight increase in overall survival (OS) (HR 0.84, 95%CI 0.75, 0.93; moderate certainty) and progression free survival (PFS) (HR 0.52, 95%CI 0.43, 0.62; moderate certainty). Toxicity had a slightly increased risk (RR 1.19, 95%CI 0.95, 1.48; low certainty). Immunotherapy also showed a likely improvement in PFS (HR 0.60, 95%CI 0.49, 0.73; moderate certainty) while toxicity showed a likely higher risk (RR 2.72, 95% CI 1.24, 5.94; moderate certainty). However, benefits in survival translated to time gains slightly over a month for OS and less than a month for PFS. No data were reported on performance status (PS), hospital admissions, or quality of life (QoL). Conclusions Our study suggests some survival benefits with low toxicity from these treatments, but gains are marginal. Uncertainties persist regarding their impact on QoL and outcomes for patients with poor PS. Caution is advised in treatment selection for advanced patients, who should actively participate in decision-making. Future research should include diverse patient populations and assess patient-centered outcomes with consistent comparator groups for BSC. Registration The study protocol was registered in OSF (https://doi.org/10.17605/OSF.IO/7CHX6) on 2022-04-01.

show abstract

The relationship between Eastern Cooperative Oncology Group performance status and healthcare resource utilization among patients with advanced or metastatic colorectal, lung or gastric cancer

Cited by 7 publications

References 12 publications

Prognostic Value of Combing Primary Tumor and Nodal Glycolytic–Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis

Prognostic Value of Combing Primary Tumor and Nodal Glycolytic–Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis

The Survival Efficiency of Initial Surgical Treatment in Stage IIIa-N2 Positive Non-Small Cell Lung Cancer

Immunotherapy or targeted therapy versus best supportive care for advanced gastric cancer: a systematic review and meta-analysis of randomized trials

Contact Info

Product

Resources

About